Changes in Hong Kong stocks | Shiyao Group (01093) rose more than 12% after results, and the reported profit attributable to mid-term shareholders increased nearly 1.4 times year-on-year

The Zhitong Finance App learned that Shiyao Group (01093) rose by more than 12% after the results. As of press release, it had risen 11.97% to HK$9.725, with a turnover of HK$3,057 billion.

According to the news, on the afternoon of August 20, Shiyao Group announced its 2026 interim results, with total revenue of 18.594 billion yuan (RMB, same below), up 40.1% year on year; shareholders' reported profit of 6.094 billion yuan, up 139.2% year on year; basic profit per share of 53.45 points. It is proposed to pay an interim dividend of HK18.00 cents per share.

In the first half of 2026, the Group obtained a total of 30 IND approvals, 7 key products were approved for listing, and 18 additional key phase III clinical studies were carried out. In the first half of 2026 alone, the Group published 14 research results, including 5 oral reports, which received good international response and widespread industry attention. Currently, the Group has more than 200 innovative drugs and innovative formulations, including 90 macromolecules, 60 small molecules, and more than 50 novel formulations. Among them, there is no shortage of products with broad market prospects and significantly superior to existing treatments in terms of efficacy and safety.